R Wieder
Overview
Explore the profile of R Wieder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fenig E, Kanfi Y, Wang Q, Beery E, Livnat T, Wasserman L, et al.
Breast Cancer Res Treat
. 2002 Jan;
70(1):27-37.
PMID: 11767002
Recent studies from our laboratory have revealed that basic fibroblast growth factor (bFGF) selectively inhibits the proliferation of human MCF-7 breast cancer cells. It has also been shown to enhance...
2.
Wang Q, Lee D, Sysounthone V, Chandraratna RAS , Christakos S, Korah R, et al.
Breast Cancer Res Treat
. 2001 Aug;
67(2):157-68.
PMID: 11519864
Vitamin D3 derivatives and retinoids can induce cell cycle arrest, differentiation and cell death in many cell lines. These compounds can act cooperatively in some of their functions and may...
3.
Korah R, Sysounthone V, Scheff E, Wieder R
Biochem Biophys Res Commun
. 2000 Oct;
277(1):255-60.
PMID: 11027671
To test the implicated role of basic fibroblast growth factor (bFGF; FGF-2) in promoting differentiation in breast cancer, we enforced the expression of FGF-2 in T-47D breast cancer cells. Expression...
4.
Wang Q, Yang W, Uytingco M, Christakos S, Wieder R
Cancer Res
. 2000 Apr;
60(7):2040-8.
PMID: 10766196
We investigated the capacity of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and all-trans-retinoic acid (ATRA) to sensitize three breast cancer cell lines to the cell killing effects of paclitaxel (Taxol) and Adriamycin, two...
5.
Korah R, Sysounthone V, Golowa Y, Wieder R
Cancer Res
. 2000 Feb;
60(3):733-40.
PMID: 10676661
Basic fibroblast growth factor (FGF-2) expression is associated with a more differentiated phenotype, earlier stage of disease, and a better prognosis in breast cancer patients. To determine whether expression of...
6.
Maloof P, Wang Q, Wang H, Stein D, Denny T, Yahalom J, et al.
Breast Cancer Res Treat
. 1999 Nov;
56(2):153-67.
PMID: 10573108
Basic fibroblast growth factor (bFGF, FGF-2), a classical transforming factor, mitogen, and survival factor in multiple cell types, and has a paradoxic role in mammary epithelial cell transformation and proliferation....
7.
Fenig E, Livnat T, Wasserman L, Beery E, Lilling G, Yahalom J, et al.
J Cancer Res Clin Oncol
. 1999 Sep;
125(10):556-62.
PMID: 10473868
Basic fibroblast growth factor (bFGF) is a classical mitogen in fibroblasts and endothelial cells. Our previous studies have demonstrated that bFGF inhibits the growth of MCF-7 human breast cancer cells....
8.
Wieder R, Fenig E, Wang H, Wang Q, Paglin S, Menzel T, et al.
J Cell Physiol
. 1998 Nov;
177(3):411-25.
PMID: 9808150
Basic fibroblast growth factor (bFGF, FGF-2) is progressively lost from mammary epithelial cells as they become malignant. To investigate the effects of restoring the expression of bFGF in breast cancer...
9.
Wang Q, Maloof P, Wang H, Fenig E, Stein D, Nichols G, et al.
Exp Cell Res
. 1998 Feb;
238(1):177-87.
PMID: 9457070
Basic fibroblast growth factor (bFGF) is a mitogen and a survival factor in fibroblasts and endothelial cells. It acts as an angiogenesis factor in breast cancer, but paradoxically inhibits proliferation...
10.
Wang H, Rubin M, Fenig E, DEBLASIO A, Mendelsohn J, Yahalom J, et al.
Cancer Res
. 1997 May;
57(9):1750-7.
PMID: 9135019
Basic fibroblast growth factor (bFGF), a classical mitogen in fibroblasts and endothelial cells, inhibits the proliferation of MCF-7 and other human breast cancer cell lines. To explain this paradoxic effect,...